3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
23
Breast
5
Other hematologic neoplasm
3
Lymphoid
3
Gynecologic
2
CNS
2
Gastrointestinal
1
Endocrine
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
115
Myelodysplastic Syndromes
107
Leukemia
98
Leukemia, Myeloid, Acute
92
Anemia
70
Leukemia, Myelomonocytic, Chronic
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
67
Myeloproliferative Disorders
55
Leukemia, Lymphocytic, Chronic, B-Cell
52
Multiple Myeloma
48
Anemia, Refractory
48
Thrombocytopenia
45
Lymphoma
43
Lymphoma, Non-Hodgkin
42
Neoplasms
40
Hodgkin Disease
39
Primary Myelofibrosis
36
Leukemia, Myeloid, Chronic-Phase
36
Congenital Abnormalities
34
Anemia, Aplastic
34
Myelodysplastic-Myeloproliferative Diseases
33
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
33
Leukemia, Myeloid, Accelerated Phase
32
Lymphoma, Follicular
29
Blast Crisis
27
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
26
Burkitt Lymphoma
25
Lymphoma, Mantle-Cell
24
Neoplasms, Plasma Cell
23
Lymphoma, B-Cell, Marginal Zone
23
Interventions
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Obesity
×
Classical hematology
×
Clear all
NCT03297359
2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2
Terminated
92 enrolled